跳至主要内容
临床试验/TCTR20220817005
TCTR20220817005招募中1 期

Effects of High-Intensity Interval Aerobic Training on Hepatic Fat Content and Liver Stiffness in Overweight and Obese Subjects with Non-Alcoholic Fatty Liver Disease

Research affairs, Faculty of Medicine, Chulalongkorn University0 个研究点目标入组 46 人开始时间: 2022年8月17日最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
发起方
入组人数
46

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 50 Years(—)
性别
All

入选标准

  • 1.Male and female in reproductive age
  • 2.Age 18-50 years old
  • 3.Severe steatosis : Controlled Attenuation Parameter (CAP) score more than or equal 310 dB/m
  • 4.Body Mass Index : BMI = 25-34.9 kg/m2
  • 5.Sedentary lifestyle

排除标准

  • 1.Pregnancy or prepared to pregnancy in 6 months
  • 2.CAP score equal or more than 400 dB/m
  • 3.Alcoholic fatty liver disease (20 g. in female and 30 g. in male)
  • 4.Fibrosis-4 (FIB-4) index equal more than 3.25, NAFLD fibrosis score (NFS) equal or more than 0.67 or liver stiffness measurement (LSM) equal or more than 10 kPa
  • 5.Other liver deseases included hepatitis B virus (HBV), hepatitis C virus (HCV), autoimmune liver disease, celiac disease, genetic disorders such as Wilson's disease, and alpha-1-antitrypsin deficiency, hepatic malignancies, hepatobiliary infections, and biliary tract disease
  • 6.Cardiac abnormalities detected by resting EKG and during exercise stress test with 12-lead EKG such as ischemic heart disease or other abnormalities that may be affected to exercise or did not pass the exercise stress test
  • 7.High blood pressure during exercise stress test (more than 250/115 mmHg)
  • 8.Injury or pain affected to exercise training
  • 9.There are risks/contraindications for testing such as myocardial ischemia of at least 6 weeks, uncontrolled arrhythmia, etc.
  • 10.Use drugs or supplements such as vitamin E, pioglitazone and liraglutide (if used, stop more than 3 months)
  • 11.Diabetes mellitus with insulin injection

研究者

发起方
Research affairs, Faculty of Medicine, Chulalongkorn University

相似试验